1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy
| Autor: | Shah, N.J., Campbell, M.T., Mao, S., Ornstein, M.C., Haas, N.B., Gao, X., Hammers, H., Keshava-Prasad, H., Hoimes, C.J., Hussain, A., George, S., Gourdin, T.S., Nelson, A., Yan, H., Esquibel, V., McIntyre, G., Geller, R., Voss, M.H., Rini, B.I., Beckermann, K. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S1016-S1017 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|